Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2007
|
| gptkbp:ATCCode |
J05AX08
|
| gptkbp:CASNumber |
518048-05-0
|
| gptkbp:chemicalFormula |
C20H20FKN6O5
|
| gptkbp:drugClass |
protease inhibitor
|
| gptkbp:eliminationHalfLife |
9 hours
|
| gptkbp:firstBook |
yes
|
| gptkbp:form |
gptkb:tablet
oral suspension chewable tablet |
| gptkbp:genericName |
gptkb:raltegravir
|
| https://www.w3.org/2000/01/rdf-schema#label |
Isentress
|
| gptkbp:indication |
treatment of HIV-1 infection in adults and children
|
| gptkbp:legalStatus |
Rx-only
|
| gptkbp:manufacturer |
gptkb:Merck_&_Co.
|
| gptkbp:metabolism |
liver (UGT1A1)
|
| gptkbp:pregnancyCategory |
C
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
fatigue headache insomnia |
| gptkbp:usedFor |
HIV infection
|
| gptkbp:bfsParent |
gptkb:Merck_&_Co.
|
| gptkbp:bfsLayer |
4
|